Review: taking Multaq and Effexor together


Summary

Drug interactions are reported among people who take Multaq and Effexor together. This review analyzes the effectiveness and drug interactions between Multaq and Effexor. It is created by eHealthMe based on reports of 21 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Multaq and Effexor >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Multaq

Multaq has active ingredients of dronedarone hydrochloride. It is often used in atrial fibrillation/flutter. (latest outcomes from Multaq 5,933 users)

Effexor

Effexor has active ingredients of venlafaxine hydrochloride. It is often used in depression. (latest outcomes from Effexor 60,435 users)

On Aug, 25, 2016

21 people who take Multaq, Effexor are studied.


Number of reports submitted per year:

Multaq and Effexor drug interactions.

Drug effectiveness over time:

Multaq:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Effexor:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Multaq:
  • female: 0.0% - (0 of 0 people)
  • male: 0.0% - (0 of 1 people)
Effexor:
  • female: 0.0% - (0 of 0 people)
  • male: 0.0% - (0 of 1 people)

Drug effectiveness by age:

Multaq:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 1 people)
Effexor:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • pulmonary oedema
  • cardiac failure
  • drug ineffective
  • dyspnoea
  • international normalised ratio increased
  • palpitations
  • respiratory arrest
  • urinary tract infection
  • white blood cell count increased
1 - 6 months:
  • blood thyroid stimulating hormone increased
  • hypothyroidism
  • thyroxine decreased
6 - 12 months:
  • atrioventricular block complete
1 - 2 years:
  • blood creatinine increased
  • dyspnoea
  • fatigue
  • renal impairment
  • breathing difficulty
  • hypothyroidism
  • liver function test abnormal
  • metabolic syndrome
5 - 10 years:
  • breathing difficulty
not specified:
  • fatigue
  • dyspnoea
  • dizziness
  • fall
  • chronic obstructive pulmonary disease
  • emphysema
  • international normalised ratio increased
  • atrial fibrillation
  • atrial flutter
  • dysphonia

Most common drug interactions by gender *:

female:
  • fall
  • international normalised ratio increased
  • pulmonary oedema
  • chronic obstructive pulmonary disease
  • emphysema
  • cardiac failure
  • aphasia
  • atrial fibrillation
  • atrioventricular block complete
  • cardiac failure acute
male:
  • dyspnoea
  • fatigue
  • atrial flutter
  • blood creatinine increased
  • dizziness
  • dysphonia
  • hypothyroidism
  • oedema peripheral
  • pericardial effusion
  • rash

Most common drug interactions by age *:

40-49:
  • blood creatinine increased
  • dyspnoea
  • fatigue
  • renal impairment
  • hypothyroidism
  • liver function test abnormal
  • metabolic syndrome
50-59:
  • chronic obstructive pulmonary disease
  • emphysema
  • aphasia
  • compartment syndrome
  • dysarthria
  • dyspnoea
  • fall
  • hemiparesis
  • pulmonary oedema
  • quadriplegia
60+:
  • dizziness
  • oedema peripheral
  • fatigue
  • international normalised ratio increased
  • atrial fibrillation
  • atrial flutter
  • cardiac failure
  • dysphonia
  • dyspnoea
  • fall

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Multaq and Effexor?

Can you answer these questions?

More questions for: Multaq, Effexor

You may be interested in these reviews

More reviews for: Multaq, Effexor

On eHealthMe, Multaq (dronedarone hydrochloride) is often used to treat atrial fibrillation/flutter. Effexor (venlafaxine hydrochloride) is often used to treat depression. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.